The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

StocksMedium•26 March 2026•

1 min read

Medicus Pharma Reports Positive Phase 2 SkinJect Results and AI Integration Plans

Key Facts

1Medicus Pharma reported an 80% Overall Response Rate (ORR) in its Phase 2 SkinJect study for the 200µg cohort.

2Data suggests the majority of treated lesions may avoid surgery in non-melanoma skin cancer cases.

3The company is planning to integrate Agentic AI into its drug development plan.

Medicus Pharma (MDCS) has announced successful clinical data from its Phase 2 study of SkinJect, a treatment targeting non-melanoma skin cancer. The study reported a significant 80% Overall Response Rate (ORR) within the 200µg cohort, highlighting the drug's therapeutic potential. Data suggests that the majority of treated lesions could potentially avoid surgical intervention, marking a major milestone in non-invasive treatment options. In addition to clinical progress, the company revealed plans to integrate Agentic AI into its drug development pipeline. This strategic move aims to accelerate development timelines and enhance efficiency in bringing new therapies to market. These advancements reflect the company's dual focus on clinical excellence and technological innovation within the oncology sector.

Create Free Account